263 related articles for article (PubMed ID: 26020984)
1. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
Yamazaki N; Maeda Y
Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
[No Abstract] [Full Text] [Related]
2. [New hope in metastatic melanoma treatment?].
Guillot B
Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
[No Abstract] [Full Text] [Related]
3. [To outwit melanoma with its own tricks].
Bischoff A
MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
[No Abstract] [Full Text] [Related]
4. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
[No Abstract] [Full Text] [Related]
5. Clinical development of the anti-CTLA-4 antibody tremelimumab.
Ribas A
Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
[TBL] [Abstract][Full Text] [Related]
6. What can we learn from phase II adjuvant trials in melanoma?
Keilholz U; Suciu S; Eggermont AM
Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
[No Abstract] [Full Text] [Related]
7. Nivolumab success in untreated metastatic melanoma.
Wilkinson E
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
[No Abstract] [Full Text] [Related]
8. Reactive oxygen species may have antitumor activity in metastatic melanoma.
Tuma RS
J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
[No Abstract] [Full Text] [Related]
9. Nivolumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].
Queirolo P; Tanda ET
Recenti Prog Med; 2015 Dec; 106(12):608-17. PubMed ID: 26780070
[TBL] [Abstract][Full Text] [Related]
11. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
[No Abstract] [Full Text] [Related]
12. Treatment for metastatic malignant melanoma: old drugs and new strategies.
Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
[TBL] [Abstract][Full Text] [Related]
13. The place of PD-1 inhibitors in melanoma management.
Bowyer S; Lorigan P
Lancet Oncol; 2015 Aug; 16(8):873-4. PubMed ID: 26115798
[No Abstract] [Full Text] [Related]
14. New therapeutic options in systemic treatment of advanced cutaneous melanoma.
Mackiewicz-Wysocka M; Zolnierek J; Wysocki PJ
Expert Opin Investig Drugs; 2013 Feb; 22(2):181-90. PubMed ID: 23215674
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of melanoma combination immunotherapy.
Baker H
Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
[No Abstract] [Full Text] [Related]
16. Immunity unleashed in melanoma.
Erdmann MK
Lancet Oncol; 2010 Feb; 11(2):108-9. PubMed ID: 20152761
[No Abstract] [Full Text] [Related]
17. The systemic treatment of advanced cutaneous melanoma.
Logan TF
Facial Plast Surg Clin North Am; 2003 Feb; 11(1):75-85. PubMed ID: 15062290
[No Abstract] [Full Text] [Related]
18. Ipilimumab approved for metastatic melanoma.
Traynor K
Am J Health Syst Pharm; 2011 May; 68(9):768. PubMed ID: 21515855
[No Abstract] [Full Text] [Related]
19. Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.
Heppt MV; Schlaak M; Eigentler TK; Kähler KC; Kiecker F; Loquai C; Meier F; Tomsitz D; Brenner N; Niesert AC; Thonke R; Hauschild A; Berking C
Ann Oncol; 2017 Dec; 28(12):3104-3106. PubMed ID: 28950303
[No Abstract] [Full Text] [Related]
20. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]